Evidence map›Paper›PMID 37682366›Full record

Observational studyNeurosurgical review2023

A prospective cohort study on decreased serum apelin-13 levels after human aneurysmal subarachnoid hemorrhage: associations with severity and prognosis.

Qun Lin, Liangzhi Ye, Junxia Dai, Zhengrong Ye, Huajun Ba, Zhiwei Li, Xiaoxiang Chen, Maohua Chen, Chuan Lu, Jun Sun and 1 more

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Neurosurgical review, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Qun LinDepartment of Neurosurgery, The Wenzhou Central Hospital, The Dingli Clinical College of Wenzhou Medical University, 252 Bailidong Road, Wenzhou, 325000, China.
Liangzhi YeDepartment of Neurosurgery, The Wenzhou Central Hospital, The Dingli Clinical College of Wenzhou Medical University, 252 Bailidong Road, Wenzhou, 325000, China.
Junxia DaiDepartment of Neurosurgery, The Wenzhou Central Hospital, The Dingli Clinical College of Wenzhou Medical University, 252 Bailidong Road, Wenzhou, 325000, China.
Zhengrong YeThe Central Blood Station of Wenzhou, 451 Nixian Road, Wenzhou, 325026, China.
Huajun BaDepartment of Neurosurgery, The Wenzhou Central Hospital, The Dingli Clinical College of Wenzhou Medical University, 252 Bailidong Road, Wenzhou, 325000, China.
Zhiwei LiDepartment of Neurosurgery, The Wenzhou Central Hospital, The Dingli Clinical College of Wenzhou Medical University, 252 Bailidong Road, Wenzhou, 325000, China.
Xiaoxiang ChenDepartment of Neurosurgery, The Wenzhou Central Hospital, The Dingli Clinical College of Wenzhou Medical University, 252 Bailidong Road, Wenzhou, 325000, China.
Maohua ChenDepartment of Neurosurgery, The Wenzhou Central Hospital, The Dingli Clinical College of Wenzhou Medical University, 252 Bailidong Road, Wenzhou, 325000, China.
Chuan LuDepartment of Neurosurgery, The Wenzhou Central Hospital, The Dingli Clinical College of Wenzhou Medical University, 252 Bailidong Road, Wenzhou, 325000, China.
Jun SunDepartment of Neurosurgery, The Wenzhou Central Hospital, The Dingli Clinical College of Wenzhou Medical University, 252 Bailidong Road, Wenzhou, 325000, China.
Jianyong CaiDepartment of Neurosurgery, The Wenzhou Central Hospital, The Dingli Clinical College of Wenzhou Medical University, 252 Bailidong Road, Wenzhou, 325000, China. wzlqcjy@163.com.
Wenzhou Medical University · CNWenzhou Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Apelin-13 may have neuroprotective effects. We aimed to determine whether serum apelin-13 could serve as a potential biomarker for severity, delayed cerebral ischemia (DCI), and prognosis after human aneurysmal subarachnoid hemorrhage (aSAH). In this prospective, observational, cohort, single-center study of 139 patients with aSAH and 139 healthy individuals, serum apelin-13 levels were determined. The indicators of stroke severity were the Hunt-Hess scale and the modified Fisher grading scale. The prognostic parameters were DCI and 6-month worse prognosis (Extended Glasgow Outcome Scale scores of 1-4). Using binary logistic regression analysis, the relationship between serum apelin-13 levels and prognosis was reported as odds ratios (ORs) with 95% confidence intervals (CIs). Under the receiver operating characteristic curve, prognostic abilities were shown as areas under the curve (AUCs) with 95% CIs. Serum apelin-13 levels were substantially lower in patients than in controls (median, 28.8 versus 48.6 ng/ml; P < 0.001), in patients with DCI than in non-DCI patients (median, 14.9 versus 31.6 ng/ml; P < 0.001), and in patients with worse prognosis than in those with good prognosis (median, 16.3 versus 33.7 ng/ml; P < 0.001). Serum apelin-13 levels were independently correlated with Hunt-Hess scores (beta, -6.836; 95% CI, -8.963-4.708; VIF, 2.219; P = 0.001) and modified Fisher scores (beta, -3.350; 95% CI, -6.151-0.549; VIF, 1.562; P = 0.019). Serum apelin-13 levels were an independent predictor of DCI (OR, 0.951; 95% CI, 0.914-0.990; P = 0.022) and worse prognosis (OR, 0.954; 95% CI, 0.916-0.993; P = 0.013). Serum apelin-13 levels significantly differentiated DCI and poor prognosis, with AUCs of 0.753 (95% CI, 0.656-0.850) and 0.791 (95% CI, 0.713-0.868) respectively. Using the Youden method, serum apelin-13 levels < 19.3 ng/ml distinguished the risk of DCI with 64.7% sensitivity and 77.1% specificity, and serum apelin-13 levels < 30.2 ng/ml discriminated the development of worse prognosis with 89.1% sensitivity and 63.4% specificity. Serum apelin-13 levels combined with Hunt-Hess scores and modified Fisher scores displayed a significantly higher AUC than any one of them for prognostic prediction (all P < 0.05). Decreased serum apelin-13 levels, which are strongly correlated with disease severity, independently predicted poor outcomes following aSAH, substantializing serum apelin-13 as a useful prognostic biomarker of aSAH.

Indexed as

Subarachnoid HemorrhageCerebral InfarctionHumansIntercellular Signaling Peptides and ProteinsPrognosisProspective Studiesapelin-13 peptideIntercellular Signaling Peptides and ProteinsAneurysmApelin-13Delayed cerebral ischemiaPrognosisSeveritySubarachnoid hemorrhage

Identifiers

PMID37682366
OpenAlexW4386529605

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.